325 related articles for article (PubMed ID: 32193810)
21. Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USA.
Ding Z; Obando C; Muser E; Kozma C; Slaton T
Drugs Real World Outcomes; 2021 Dec; 8(4):565-575. PubMed ID: 34136998
[TBL] [Abstract][Full Text] [Related]
22. Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease.
Shiga H; Tarasawa K; Moroi R; Makuuchi M; Takahashi T; Shimoyama Y; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Nov; 37(11):2105-2112. PubMed ID: 36059265
[TBL] [Abstract][Full Text] [Related]
23. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
[TBL] [Abstract][Full Text] [Related]
24. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
[TBL] [Abstract][Full Text] [Related]
25. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
26. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
27. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
28. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
29. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
30. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.
Kim FS; Patel PV; Stekol E; Ali S; Hamandi H; Heyman MB; Verstraete SG
J Pediatr Gastroenterol Nutr; 2021 Nov; 73(5):610-614. PubMed ID: 34415711
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
[TBL] [Abstract][Full Text] [Related]
32. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
[TBL] [Abstract][Full Text] [Related]
33. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.
Liu R; Li Z; Ye L; Hu J; Tang J; Chen B; Chen X; Tan B; Gu Y; Xie C; Ouyang C; Song X; Li F; Fan Y; Ren H; Zhu L; Chen M; Jiang W; Cao Q
Inflamm Bowel Dis; 2024 Jan; 30(1):45-52. PubMed ID: 36880432
[TBL] [Abstract][Full Text] [Related]
34. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
35. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.
Cortes X; Borrás-Blasco J; Antequera B; Fernandez-Martinez S; Casterá E; Martin S; Molés JR
J Clin Pharm Ther; 2017 Apr; 42(2):234-236. PubMed ID: 28004853
[TBL] [Abstract][Full Text] [Related]
36. Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA.
Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
Adv Ther; 2020 Jun; 37(6):2777-2791. PubMed ID: 32399813
[TBL] [Abstract][Full Text] [Related]
37. A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan.
Liu Y; Goh CH; Qiu H; Huang KC; Chung H; Saadoun C
Ann Pharmacother; 2023 Sep; 57(9):1053-1061. PubMed ID: 36602021
[TBL] [Abstract][Full Text] [Related]
38. The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States.
Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
Womens Health (Lond); 2020; 16():1745506520965898. PubMed ID: 33357086
[TBL] [Abstract][Full Text] [Related]
39. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
Miyatani Y; Choi D; Choi NK; Rubin DT
Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
[TBL] [Abstract][Full Text] [Related]
40. Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's disease.
Bessissow T; Narula N; Ma C; In TSH; Pone E; Eberg M; Jairath V;
Dig Liver Dis; 2024 May; ():. PubMed ID: 38821813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
